Familial Brain Tumours

Developments in Oncology

Book 9
Springer Science & Business Media
Free sample

Heredity, environment, the role of infectious agents, and other influences have been cited within a multiplicity of factors of possible relevance to the problem of neoplasm etiology. In some cases, such as that of retinoblastoma the influence of hereditary factors has been clearly established. The influence of genetic factors in cerebral tumour development has been under discussion since as early as 1896 when Besold reported two sisters suffering from brain tumours. Although much more is now known about the classification, prognosis, and treatment of these tumours, and a number of familial cases have been reported, the present data are insufficient to permit conclusions regarding the influence of hereditary factors in the etiology of most types of cerebral neoplasms, and research in this area is urgently required. Research on familial brain tumours must still be largely based upon the cumulative case histories which have been reported. Although a number of papers contain historical reviews, some in tabulated form, the actual data have not been readily available to the researcher, each investigator being obliged to compile anew all reports published on the subject over an 80 year period. This book represents an attempt by the present authors to assemble the pertinent data on individual cases of familial brain tumours published since 1896. For this purpose the essential information from the original articles in German, French, Dutch, Spanish, Italian, Polish, and Czechoslovakian have been translated into English.
Read more

Additional Information

Springer Science & Business Media
Read more
Published on
Dec 6, 2012
Read more
Read more
Read more
Read more
Best For
Read more
Read more
Medical / Clinical Medicine
Medical / Oncology
Read more
Content Protection
This content is DRM protected.
Read more

Reading information

Smartphones and Tablets

Install the Google Play Books app for Android and iPad/iPhone. It syncs automatically with your account and allows you to read online or offline wherever you are.

Laptops and Computers

You can read books purchased on Google Play using your computer's web browser.

eReaders and other devices

To read on e-ink devices like the Sony eReader or Barnes & Noble Nook, you'll need to download a file and transfer it to your device. Please follow the detailed Help center instructions to transfer the files to supported eReaders.
F. M. MUGGIA When faced with the inadequacies of current cancer treatment, we prefer to look at what the future may hold. Quite often, we take for granted the past, preferring research into totally new areas. However, the persistent development of fertile soil may yield surprising rewards for those who choose to build on the knowledge of the past--hence, this symposium on anthracycline antibiotics. Although the anthracycline antibiotics represent much of the present and future of cancer treatment, their actual use c stretches back barely two decades to the pioneering efforts of Aurelio Di Marco, who characterized the antitumor properties of daunomycin and adriamycin. * The clinical application of these two compounds heralded a decade of excitement among oncologists dealing with pediatric tumors, breast cancer, leukemias, and lymphomas, and opened new hope for patients afflicted with sar comas and a variety of other tumors that had been deemed - sistant to chemotherapy. These successes were tempered with the realization that the antitumor effect of anthracyclines could be achieved at times only at the very high price of risking cardiac decompensation and, almost invariably, with the occurrence of alopecia and other acute toxicities. This record of past achievements and problems has slowly given way to a present increasingly illuminated by our ability to modify the distressing toxicities of these agents. Detailed clinical studies supplemented by ingenious laboratory models have gradually elucidated mechanisms and risk factors im plicated in the cardiomyopathy.
In 1978 the Dutch Genetic SOciety organized a symposium on the genetic aspects of the origin of tumor cells. The objective of this symposium was to reach an overview of the state of knowledge in a number of quite different fields related to each other through the genetics of the initiation of tumor cells. This monograph contains the brought-up-to-date contributions of this symposium. Herein discussed is the extent that characteristics of tumor cells can be considered as a phenotype. The possible role of somatic mutation and repair of genetic damage is studied and the analysis of genes with oncogenic potential is pursued. Also the influence of host factors in the response to oncogenic action is dealt with. This volume describes in a clear and concise manner the current status in these research areas and, it is hoped, will stimulate the exchange of information and ideas between them. Dr. F.l. CLETON, The Netherlands Cancer Institute, Amsterdam Dr. J.W.I.M. SIMONS, Department of Radiation Genetics and Chemical Mutagenesis, University of Leiden CONTRIBUTORS P. Bentvelzen Ph. D. Radiobiological Institute TNO, Lange Kleiweg 151, Rijswijk (ZH), The Nether lands. F.I. Cleton M.D. Antoni van Leeuwenhoek-Huis, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands. P. Demant M.D. Antoni van Leeuwenhoek-Huis, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands. A.I. van der Eb Ph. D., H. Iochemsen, I.H. Lupker, I. Maat, H. van Ormondt, P.1. Schrier.
With a new foreword by Dr. Dominic D'Agostino, PhD and epilogue by the author

A masterful synchronization of history and cutting-edge science shines new light on humanity's darkest diagnosis.

In the wake of the Cancer Genome Atlas project's failure to provide a legible roadmap to a cure for cancer, science writer Travis Christofferson illuminates a promising blend of old and new perspectives on the disease. Tripping over the Truth follows the story of cancer’s proposed metabolic origin from the vaunted halls of the German scientific golden age to modern laboratories around the world. The reader is taken on a journey through time and science that results in an unlikely connecting of the dots with profound therapeutic implications.

Transporting us on a rich narrative of humanity’s struggle to understand the cellular events that conspire to form malignancy, Tripping over the Truth reads like a detective novel, full of twists and cover-ups, blind-alleys and striking moments of discovery by men and women with uncommon vision, grit, and fortitude. Ultimately, Christofferson arrives at a conclusion that challenges everything we thought we knew about the disease, suggesting the reason for the failed war against cancer stems from a flawed paradigm that categorizes cancer as an exclusively genetic disease.

For anyone affected by this terrifying disease and the physicians who struggle to treat it, this book provides a fresh and hopeful perspective. It explores the new and exciting non-toxic therapies born from the emerging metabolic theory of cancer. These therapies may one day prove to be a turning point in the struggle against our ancient enemy. We are shown how the metabolic theory redraws the battle map, directing researchers to approach cancer treatment from a different angle, framing it more like a gentle rehabilitation rather than all-out combat. In a sharp departure from the current “targeted” revolution occurring in cancer pharmaceuticals, the metabolic therapies highlighted have one striking feature that sets them apart—the potential to treat all types of cancer because they exploit the one weakness that is common to every cancer cell: dysfunctional metabolism.

With contributions from Thomas Seyfried, PhD, author of Cancer as a Metabolic Disease; Miriam Kalamian, EdM, MS, CNS, author of Keto for Cancer; and Beth Zupec Kania, consultant nutritionist of The Charlie Foundation.

©2018 GoogleSite Terms of ServicePrivacyDevelopersArtistsAbout Google|Location: United StatesLanguage: English (United States)
By purchasing this item, you are transacting with Google Payments and agreeing to the Google Payments Terms of Service and Privacy Notice.